ICD Guidelines From ACC/AHA/NASPE Embrace MADIT-II Prophylactic Use
This article was originally published in The Gray Sheet
Executive Summary
ICDs should be implanted in heart attack victims whose left-ventricular ejection fraction is 30% or less one month after the event and three months post-revascularization, according to new practice guidelines issued jointly by ACC, AHA and NASPE
You may also be interested in...
Starts & Stops: Boston Scientific Starts, Stops, And Finishes TAVR Trials
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This month's edition includes seven trial-terminations – not as many as last month, but more than usual – for a variety of reasons, including Boston Scientific's suspension of all its trials of the Lotus transcatheter aortic valve due to a manufacturing problem.
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations
Generalizability Of Prophylactic ICD Benefits Questioned By CMS, Panelists
CMS' reliance on the precise wording of Guidant's original national coverage determination request for expanded ICD use suggests the need for companies to tailor their requests to avoid overly broad interpretations